The 7th Annual


Johns Hopkins Postdoctoral Conference

JHPDC

NOTE: In light of the rapidly escalating COVID-19 situation, we have reschedule the JHPDC 2020 for Tuesday, August 18th, 2020.

 The Johns Hopkins Postdoctoral Association (JHPDA) and the Homewood Postdoctoral Association (HW-PDA) invite you to our 7th Annual Postdoctoral Conference on Tuesday, August 18th, 2020.

The conference is open to postdocs in the DMV Area including, but not limited to:

  • All Johns Hopkins schools and institutes (incl. Homewood, Carey, SIS, etc)
  • Carnegie Institution for Science, Baltimore
  • NIH Bayview campus
  • University of Maryland, Baltimore (UMB)
  • University of Maryland, College Park (UMD)

Registration Deadline: August 7th, 2020

Abstract Registration Deadline: August 3rd, 2020

Abstract submission is not required to partake in the conference, but registration is mandatory for postdocs. Registration is not mandatory for students and faculty – please register onsite.

Please note that registration and abstract submission use a single form — register and submit your abstract at the same time. We do not allow separate registration and abstract submission, but there is an option to register only if you do not wish to submit an abstract.

This year there is a separate submission form for the Postdoc Slam, which is replacing the oral presentations. Abstracts are required only for poster presentations, as the Postdoc Slam requires a video submission or in-person presentation. More information coming soon. We encourage Hopkins postdocs interested in the Postdoc Slam to also submit an abstract.

IMPORTANT: Abstract submission ends on August 3rd. Abstracts submitted after this date will NOT be accepted.

Keynote Speakers

Martina Rauner, PhD

Professor of Molecular Bone Biology, Dresden

Aris Economides, PhD

Vice President of Regeneron Pharmaceuticals, New York

Martina Rauner studied biotechnology at the University of Applied Sciences in Vienna, Austria from 2002-2006. After completing her doctorate at the Department of Pathophysiology at the Medical University of Vienna in 2008, she received the ECTS/AMGEN bone research fellowship and joined the group of Professor Lorenz Hofbauer in Dresden, Germany to study mechanisms of glucocorticoid-induced osteoporosis. In 2011, Martina became Group leader for Osteoimmunology and expanded her research area to chronic inflammatory diseases and Wnt signaling. Due to her comprehensive knowledge on bone biology, its interactions with other organ systems, and her leadership skills, she was promoted to the Scientific Director of the Bone lab in 2015 and became Professor for Molecular Bone Biology in 2018. Currently, her group is particularly interested in the interactions of bone with hematopoiesis, the immune system, and hormones (glucocorticoids, erythropoietin, and thyroid hormones), and studies the role of Wnt and BMP signaling.

Martina has published over 100 publications in the field of bone biology and has received several awards for her work. Moreover, she was on the board of the European Calcified Tissue Society (ECTS) from 2012-2018, has promoted the needs of New Investigators in that society, and is a founding member of the ECTS Academy, a group of outstanding young scientists in the musculoskeletal field. Moreover, she is a member of several ASBMR committees.

Dr. Aris N. Economides received his Ph.D. in Biochemistry from Michigan State University in 1992, and promptly joined Regeneron Pharmaceuticals. He currently holds the position of Vice President, leading two groups: Genome Engineering Technologies, and Skeletal Diseases Therapeutic Focus Area. In addition, he is a co-founder of Regeneron Genetics Center (RGC), where he is also Head of Functional Modeling. Dr. Economides co-invented Cytokine Traps, VelociGene®, and VelocImmune®, all part of an integrated methodology for target discovery, validation, and the generation of biologic drugs such as the IL1 and VEGF traps, as well as therapeutic antibodies. More recently, he has been developing a new method for Enzyme Replacement Therapy (ERT), one that addresses two of the main limitations of current ERT, namely immunogenicity and inefficient uptake by the tissues most affected in the corresponding Lysosomal Diseases. As part of his involvement with the RGC, Dr. Economides has been working to elucidate the molecular pathophysiology of genetically-driven disorders. An example is his work in Fibrodysplasia Ossificans Progressiva, where he and his team discovered a novel mechanism that explains important aspects of FOP’s pathophysiology and pinpoints a new potential route to therapy.

Sponsored by: